MedTrace Logo

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

NCT03774784 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2020-06-16

No results posted yet for this study

Summary

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.

Conditions

  • Amyloidosis
  • Leukocyte Chemotactic Factor 2 Amyloidosis

Sponsors & Collaborators

Principal Investigators

  • Joshua Friedman, MD · Alnylam Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-29
Primary Completion
2020-05-18
Completion
2020-05-18

Countries

  • United States
  • Egypt
  • India
  • Malaysia
  • Mexico
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774784 on ClinicalTrials.gov